

NATA Accreditation Awarded for Genetype Laboratory Operations

Highlights

- ✓ Reinstatement of NATA accreditation for the Genetype risk assessment portfolio
- ✓ A key milestone for securing ColoSTAT® accreditation and commercial launch as an in house IVD.

Melbourne, Australia, 24th June 2025: Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX:RHY), a transformative, predictive cancer diagnostics technology company, is pleased to announce that it has attained NATA accreditation for the geneType™ cancer risk assessment assay portfolio.

Following the transfer of the Genetype assets to Rhythm during the asset acquisition from Genetic Technologies Ltd earlier in 2025, the previously held Genetype NATA accreditation was temporarily suspended (accreditation number 20432). Rhythm has now secured full reinstatement of this accreditation which completes the laboratory integration.

This milestone marks the successful conclusion of the integration of the Genetype laboratory under Rhythm's ownership and ensures continuity of accredited testing services moving forward.

Importantly, this reinstatement is also crucial for advancing the Company's ColoSTAT® commercialisation strategy. With an ISO 15189-accredited quality system now under Rhythm's control, we are positioned to progress ColoSTAT® as an in-house IVD subject to the completion by the Company of a variation assessment to add ColoSTAT® as a Rhythm accredited service. This will allow the Company to deploy ColoSTAT® in a clinical setting and generate real-world performance data — an essential step in our objective to ultimately commercialise ColoSTAT® globally as a regulated *in vitro* diagnostic.

Dr. David Atkins, CEO and MD: *"Reinstating NATA accreditation for Genetype is an important enabler for our plans to scale the clinical availability of this important portfolio of cancer risk assessment assays. Furthermore, this is a significant stepping stone to allow us to offer ColoSTAT® as an in house IVD for the domestic market in the coming months."*

Directors

Otto Buttula
Sue MacLeman
Gavin Fox-Smith
David Atkins

Non-Executive Chairman
Non-Executive Director
Non-Executive Director
CEO & Managing Director

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT[®]

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT[®] Test-Kit is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet relevant regulatory standards.

The ColoSTAT[®] Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType[™]

geneType[™] is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.